(NASDAQ: NAMS) Newamsterdam Pharma Co Nv's forecast annual revenue growth rate of 5.19% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.04%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.92%.
Newamsterdam Pharma Co Nv's revenue in 2024 is $15,315,217.On average, 3 Wall Street analysts forecast NAMS's revenue for 2024 to be $871,778,329, with the lowest NAMS revenue forecast at $357,066,692, and the highest NAMS revenue forecast at $1,856,746,798. On average, 1 Wall Street analysts forecast NAMS's revenue for 2025 to be $883,740,063, with the lowest NAMS revenue forecast at $883,740,063, and the highest NAMS revenue forecast at $883,740,063.
In 2026, NAMS is forecast to generate $1,671,518,452 in revenue, with the lowest revenue forecast at $531,136,704 and the highest revenue forecast at $2,811,900,200.